




RealRate

PHARMACEUTICAL 2019

Ayala Pharmaceuticals Inc
Rank 285 of 361

ADVAXIS
IMMUNOTHERAPIES™



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Ayala Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Ayala Pharmaceuticals Inc compared to the market average is the variable Liabilities, Non-Current, increasing the Economic Capital Ratio by 1.7% points. The greatest weakness of Ayala Pharmaceuticals Inc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 80% points.

The company's Economic Capital Ratio, given in the ranking table, is 140%, being 109% points below the market average of 250%.

Input Variable	Value in 1000 USD
Assets, Current	50,465
Cost of Goods Sold	0
Intangible Assets	4,838
Liabilities, Current	22,872
Liabilities, Non-Current	1,155
Other Assets	280
Other Compr. Net Income	0
Other Expenses	50
Other Liabilities	14,189
Other Net Income	3,914
Other Revenues	6,063
Property and Equipment	6,684
Research and Development	56,970
Selling, General and Administrative Expense	19,472

Output Variable	Value in 1000 USD
Assets	62,267
Liabilities	38,216
Expenses	76,492
Revenues	6,063
Stockholders Equity	24,051
Net Income	-66,515
Comprehensive Net Income	-66,515
BaseVar	93,476
ECR before Limited Liability	-28%
Economic Capital Ratio	140%